Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 U-CAR-NK Cells with HSCT for B-cell Malignancies
NCT05570188Phase 2Withdrawn
- Sponsor
- Kunming Hope of Health Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 UCAR-NK cells in B cell lymphoma and B-cell leukemia (BCL), sponsored by Kunming Hope of Health Hospital. Primary endpoint: Incidence of adverse events at 52 weeks. Planned start Oct 2022; status: withdrawn.
02
Drugs
anti-CD19 UCAR-NK cells
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT05570188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570188.